reports
Valsoia S.p.A.: 1 director
A director at Valsoia S.p.A. bought 20,000 shares at 9.080EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Augustin Socié
- Gaetan Calabro
- Jeremy Sallee
- Maxence Dhoury
- Mohamed Kaabouni
- Nicolas Royot
La Matinale - 2022-09-30 - Portzamparc
GTT : Elogen recevra une subvention PIIEC de 86M€ – Conserver (3), obj. 129.7€ Cours: 111.0€ au 29/09/22 ATEME : Le retour de l'EBITDA positif / Contact – Acheter (1), obj. 17.7€ Cours: 13.1€ au 29/09/22 AUREA : Des incertitudes au S2 – Conserver (3) vs Renforcer (2), obj. 7.50€ Cours: 7.34€ au 29/09/22 BALYO : Le contexte et la transition creusent les pertes – Arrêt du suivi Cours: 0.47€ au 29/09/22 ENERTIME : Des projets à concrétiser – Acheter (1), obj. 3.10€ Cours: 1.67€ au 29/09/22 GRO...
- Olga Smolentseva
VALNEVA - BUY | EUR15 (+64%) Strengthening vaccines pipeline in the po...
Post-COVID, we believe governments and investors will step up their focus on the infectious disease vaccines. We expect Valneva to benefit from this trend as a fully integrated pure-play vaccine company with two products on the market and two attractive late-stage candidates. In this report, we highlight the expected 2023 launch of the VLA1553 vaccine for prevention of Chikungunya disease. While we model a sales trajectory in the traveller market, we believe that with changing climate patterns, ...
- Gaetan Calabro
- Jeremy Sallee
- Mohamed Kaabouni
- Nicolas Montel
- Nicolas Royot
La Matinale - 04-02-2022
NRJ GROUP : T4 de haut vol ! / Contact – Acheter (1), obj. 10.3€ Cours: 6.04€ au 03/02/22 BONDUELLE : Recul du frais aux États-Unis – Acheter (1), obj. 25.5€ Cours: 20.7€ au 03/02/22 LINEDATA : Toujours du profit mais peu de croissance – Acheter (1), obj. 46.1€ Cours: 40.1€ au 03/02/22 LNA SANTE : T4 en ligne + Finalisation renforcement au capital / Contact – Acheter (1), obj. 55.5€ Cours: 43.0€ au 03/02/22 METABOLIC EXPLORER : T4 en ligne, guidance 2022 confirmée / Contact – Acheter (1), ob...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.